TWI815820B - ２－（５－（４－（２－嗎啉乙氧基）苯基）吡啶－２－基）－ｎ－芐乙醯胺之固態形式 - Google Patents

２－（５－（４－（２－嗎啉乙氧基）苯基）吡啶－２－基）－ｎ－芐乙醯胺之固態形式 Download PDF

Info

Publication number
TWI815820B
TWI815820B TW107131540A TW107131540A TWI815820B TW I815820 B TWI815820 B TW I815820B TW 107131540 A TW107131540 A TW 107131540A TW 107131540 A TW107131540 A TW 107131540A TW I815820 B TWI815820 B TW I815820B
Authority
TW
Taiwan
Prior art keywords
compound
polymorph
cancer
xrpd
solvent
Prior art date
Application number
TW107131540A
Other languages
English (en)
Chinese (zh)
Other versions
TW201920160A (zh
Inventor
麥可 史莫林斯基
Original Assignee
美商Ａｔｎｘ特殊目的實體公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65517772&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI815820(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 美商Ａｔｎｘ特殊目的實體公司 filed Critical 美商Ａｔｎｘ特殊目的實體公司
Publication of TW201920160A publication Critical patent/TW201920160A/zh
Application granted granted Critical
Publication of TWI815820B publication Critical patent/TWI815820B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Physics & Mathematics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW107131540A 2017-09-07 2018-09-07 ２－（５－（４－（２－嗎啉乙氧基）苯基）吡啶－２－基）－ｎ－芐乙醯胺之固態形式 TWI815820B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762555390P 2017-09-07 2017-09-07
US62/555,390 2017-09-07

Publications (2)

Publication Number Publication Date
TW201920160A TW201920160A (zh) 2019-06-01
TWI815820B true TWI815820B (zh) 2023-09-21

Family

ID=65517772

Family Applications (1)

Application Number Title Priority Date Filing Date
TW107131540A TWI815820B (zh) 2017-09-07 2018-09-07 ２－（５－（４－（２－嗎啉乙氧基）苯基）吡啶－２－基）－ｎ－芐乙醯胺之固態形式

Country Status (23)

Country Link
US (4) US10669236B2 (https=)
EP (2) EP4674486A3 (https=)
JP (3) JP7843116B2 (https=)
KR (2) KR102691700B1 (https=)
CN (2) CN111278808B (https=)
AU (2) AU2018330163B2 (https=)
BR (1) BR112020004419A2 (https=)
CA (1) CA3074831A1 (https=)
DK (1) DK3679016T3 (https=)
ES (1) ES3056703T3 (https=)
FI (1) FI3679016T3 (https=)
HR (1) HRP20260002T1 (https=)
IL (2) IL326637A (https=)
LT (1) LT3679016T (https=)
MX (2) MX2020002622A (https=)
PL (1) PL3679016T3 (https=)
PT (1) PT3679016T (https=)
RS (1) RS67706B1 (https=)
SG (1) SG11202001868RA (https=)
SI (1) SI3679016T1 (https=)
SM (1) SMT202500467T1 (https=)
TW (1) TWI815820B (https=)
WO (1) WO2019051147A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968574B2 (en) * 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
EP4186890A1 (en) 2021-11-29 2023-05-31 Moehs Ibérica, S.L. Preparation of n-benzyl-2-(5-bromo-pyridin-2-yl)-acetamide for the synthesis of tirbanibulin
CN115010655A (zh) * 2022-07-21 2022-09-06 重庆迈德凯医药有限公司 一种替尼布林的纯化方法
WO2026022219A1 (en) 2024-07-24 2026-01-29 Almirall, S.A. Injectable formulations comprising tirbanibulin

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106810490A (zh) * 2017-02-06 2017-06-09 重庆泰润制药有限公司 一种二芳基化合物的晶型及其制备方法和应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US7141593B1 (en) * 1999-06-04 2006-11-28 Abbott Laboratories Pharmaceutical formulations
ES2258142T3 (es) * 2001-05-22 2006-08-16 Pfizer Products Inc. Nueva forma cristalina.
US6821502B2 (en) * 2002-06-12 2004-11-23 Chevron U.S.A. Inc. Method of making aluminum-containing zeolite with IFR structure
US7351833B2 (en) * 2004-07-23 2008-04-01 Abbott Laboratories (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate
US7968574B2 (en) 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
ES2382068T3 (es) 2004-12-28 2012-06-05 Kinex Pharmaceuticals, Llc Composiciones y métodos para tratar trastornos de proliferación celular
MY152185A (en) * 2005-06-10 2014-08-29 Novartis Ag Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
CN101687905A (zh) * 2005-09-13 2010-03-31 西科尔公司 纯罗库溴铵
ES2500165T3 (es) 2006-06-29 2014-09-30 Kinex Pharmaceuticals, Llc Composiciones de biarilo y métodos para modular una cascada de quinasas
MX2009003405A (es) * 2006-09-28 2009-04-09 Merck & Co Inc Composiciones farmaceuticas de inhibidores de la histona desacetilasa y compuestos quelantes de metal, y complejos de quelato de metal-inhibidor de histona desacetilasa.
US7837978B2 (en) * 2006-10-13 2010-11-23 Chevron U.S.A. Inc. Process for preparing aluminum-containing molecular sieve SSZ-26
PE20081506A1 (es) * 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
US7935697B2 (en) * 2006-12-28 2011-05-03 Kinex Pharmaceuticals, Llc Compositions for modulating a kinase cascade and methods of use thereof
US7939529B2 (en) 2007-05-17 2011-05-10 Kinex Pharmaceuticals, Llc Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof
TWI457336B (zh) * 2006-12-28 2014-10-21 Kinex Pharmaceuticals Llc 調節激酶級聯之組成物及方法
AU2008253803A1 (en) * 2007-05-22 2008-11-27 Ultimorphix Technolgies B.V. Tenofovir disoproxil hemi-fumaric acid Co-crystal
WO2015069217A1 (en) * 2013-11-05 2015-05-14 Baylor College Of Medicine Src kinase inhibition as treatment for lympangioleiomyomatosis and tuberous sclerosis
FI3592355T3 (fi) 2017-03-10 2026-02-13 Atnx Spv Llc KX2-391/KX-01 käytettäväksi aktiinisen keratoosin hoidossa

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106810490A (zh) * 2017-02-06 2017-06-09 重庆泰润制药有限公司 一种二芳基化合物的晶型及其制备方法和应用

Also Published As

Publication number Publication date
CN111278808B (zh) 2024-04-26
PL3679016T3 (pl) 2026-03-02
AU2023201010A1 (en) 2023-03-23
US20190071402A1 (en) 2019-03-07
DK3679016T3 (da) 2025-12-15
IL272992A (en) 2020-04-30
JP2025131661A (ja) 2025-09-09
PT3679016T (pt) 2025-12-05
HRP20260002T1 (hr) 2026-02-27
ES3056703T3 (en) 2026-02-24
SMT202500467T1 (it) 2026-03-09
US20220098152A1 (en) 2022-03-31
CN111278808A (zh) 2020-06-12
US20200255380A1 (en) 2020-08-13
CN118439992A (zh) 2024-08-06
AU2018330163A1 (en) 2020-03-26
US10669236B2 (en) 2020-06-02
KR102691700B1 (ko) 2024-08-02
CA3074831A1 (en) 2019-03-14
AU2018330163B2 (en) 2023-02-02
SG11202001868RA (en) 2020-03-30
SI3679016T1 (sl) 2026-04-30
MX2023001805A (es) 2023-03-13
EP3679016B1 (en) 2025-11-05
RU2020112539A3 (https=) 2022-04-19
FI3679016T3 (fi) 2025-12-12
MX2020002622A (es) 2020-10-01
AU2023201010B2 (en) 2024-10-03
EP4674486A3 (en) 2026-03-25
KR20240119192A (ko) 2024-08-06
RS67706B1 (sr) 2026-02-27
KR20200081359A (ko) 2020-07-07
US12215083B2 (en) 2025-02-04
LT3679016T (lt) 2026-02-10
RU2020112539A (ru) 2021-10-08
EP4674486A2 (en) 2026-01-07
JP2020533412A (ja) 2020-11-19
BR112020004419A2 (pt) 2020-09-08
WO2019051147A1 (en) 2019-03-14
US20250115555A1 (en) 2025-04-10
IL326637A (en) 2026-04-01
EP3679016A1 (en) 2020-07-15
EP3679016A4 (en) 2021-09-29
JP2023157909A (ja) 2023-10-26
JP7843116B2 (ja) 2026-04-09
US11230527B2 (en) 2022-01-25
TW201920160A (zh) 2019-06-01

Similar Documents

Publication Publication Date Title
CN116650500B (zh) 治疗癌症的方法
US12215083B2 (en) Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-n-benzylacetamide
TW201011024A (en) Compounds and methods for kinase modulation, and indications therefor
WO2013028495A1 (en) Dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) for the treatment of multiple myeloma
CN105189513A (zh) 葡萄糖醇，1-脱氧-1-(甲胺基)-,1-(6-氨基-3,5-二氟吡啶-2-基)-8-氯-6-氟-1,4-二氢-7-(3-羟基氮杂环丁烷-l-基)-4-氧-3-喹啉羧酸盐的结晶形态
CN102351842B (zh) 甲磺酸伊马替尼的f、g、h、i 和k晶形
JP2018537486A (ja) キノロン類似体及びその塩の結晶形
CN111971272A (zh) 柳氮磺吡啶盐组合物及其使用方法
JP6656505B2 (ja) オービットアジン−フマル酸塩、水和物、結晶形及びその調製方法
RU2802964C2 (ru) Твердые формы 2-(5-(4-(2-морфолиноэтокси)фенил)пиридин-2-ил)-n-бензилацетамида
HK40115548A (zh) 2-(5-(4-(2-吗啉代乙氧基)苯基)吡啶-2-基)-n-苄基乙酰胺的固体形式
JP2020189888A (ja) キノロン類似体及びその塩の結晶形
JP2022532186A (ja) 非晶質のｐｉ３ｋ阻害剤及びこれを含有する医薬組成物
CN102666528A (zh) 晶体cdc7 抑制剂盐
TWI898321B (zh) 用於治療或預防高尿酸血症或痛風的化合物的固體晶型
CN121941687A (zh) 一种丙烯酰胺类化合物的晶型vi及其制备方法和用途
HK40108981A (zh) 4-[5-[(3S)-3-氨基吡咯烷-l-羰基]-2-[2-氟-4-(2-羟基-2-乙基丙基)苯基]苯基]-2-氟-苯甲腈的盐的固体形式